Study wrapper · #749
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes.
Editor's note
This study reports that MOTS-c declines with age and senescence in pancreatic islet cells, and that treating aged mouse islets with MOTS-c reduced markers of islet senescence by modulating nuclear gene expression and metabolites. In diabetic mouse models MOTS-c improved islet senescence and glucose intolerance, and in humans circulating MOTS-c was lower in type 2 diabetes than controls, an association. The authors frame MOTS-c as a possible "senotherapeutic." The interventional evidence is preclinical; the human arm is observational. These are preclinical findings; human data are needed before any clinical conclusions, and the abstract's talk of "delaying diabetes" reflects a mouse-model outcome, not demonstrated human benefit. It adds a coherent ageing/senescence angle to the MOTS-c metabolic literature.
Plain-language abstract
The pancreas's islet cells make insulin, and they can age and become "senescent" (worn out) over time, contributing to diabetes. Researchers found that MOTS-c, a mitochondria-derived peptide, drops as islet cells age. When they treated aged mouse islets with MOTS-c, signs of cellular ageing decreased. In diabetic mouse models, MOTS-c improved both islet ageing and the body's ability to handle glucose. They also observed that people with type 2 diabetes had lower blood MOTS-c than healthy people, though that is just an association. The authors suggest MOTS-c might act as a "senotherapeutic," a molecule that counters cellular ageing. Because the treatment results came from mice and cells, they cannot show benefit in people, and the human data only show a correlation; human trials would be needed. The study adds an ageing-and-cellular-senescence angle to the broader research on MOTS-c and metabolism.